^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    TYRO3 (TYRO3 Protein Tyrosine Kinase)

    i
    Other names: TYRO3, TYRO3 Protein Tyrosine Kinase, Tyrosine-Protein Kinase Receptor TYRO3, Tyrosine-Protein Kinase DTK, Tyrosine-Protein Kinase RSE, Tyrosine-Protein Kinase SKY, Tyrosine-Protein Kinase TIF, Etk-2, BYK, Dtk, RSE, Rek, Sky, Tif, Tyrosine-Protein Kinase Byk, Tyrosine-Protein Kinase BYK, TYRO3, Brt, DTK, SKY, TIF
    7ms
    miR-1343-3p, mediated by LncRNA ASMTL-AS1, induces ferroptosis in osteosarcoma progression by targeting TYRO3. (PubMed, Gene)
    Furthermore, the long non-coding RNA ASMTL-AS1 was identified as a competing endogenous RNA (ceRNA) for miR-1343-3p, thereby regulating TYRO3 expression. Collectively, our results reveal a novel ASMTL-AS1/miR-1343-3p/TYRO3 axis that modulates ferroptosis and OS progression, offering new insights into potential therapeutic targets for OS.
    Journal
    |
    TYRO3 (TYRO3 Protein Tyrosine Kinase) • MIR134 (MicroRNA 134)
    10ms
    Sitravatinib targets TYRO3 to augment the anti-tumor immune response of PD-1 blockade in hepatocellular carcinoma. (PubMed, Clin Cancer Res)
    Collectively, we demonstrated a rationale for combining sitravatinib with PD-1 blockade in the treatment for HCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CD8 (cluster of differentiation 8) • AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • TYRO3 (TYRO3 Protein Tyrosine Kinase) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IL33 (Interleukin 33)
    |
    sitravatinib (MGCD516)
    12ms
    Hua Zheng San Ji Fang suppresses liver cancer progression by inhibiting TYRO3 expression via the ERK signaling pathway. (PubMed, Phytomedicine)
    HZSJF alleviated liver cancer progression through the ERK signaling pathway by inhibiting TYRO3 expression, presenting a potential therapeutic approach.
    Journal
    |
    TYRO3 (TYRO3 Protein Tyrosine Kinase)
    over1year
    TYRO3 and EPHA2 Expression Are Dysregulated in Breast Cancer. (PubMed, Cell Biochem Funct)
    EPHA2 expression is also related to aging and smoking habits. The expression levels of the TAM and EPHA2 genes seem to play an important role in breast cancer, being also influenced by the patient's lifestyle.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • EPHA2 (EPH receptor A2) • TYRO3 (TYRO3 Protein Tyrosine Kinase)
    |
    MET expression
    over1year
    E3 ubiquitin ligase BTBD3 inhibits tumorigenesis of colorectal cancer by regulating the TYRO3/Wnt/β-catenin signaling axis. (PubMed, Cancer Cell Int)
    Our data further confirmed that BTBD3 bound and ubiquitinated β-catenin and led to β-catenin degradation, therefore blocked the Wnt/β-catenin pathway and suppressed the CRC tumorigenesis. This study explored the mechanism of BTBD3 involved in CRC tumorigenesis and provided a new theoretical basis for the prevention and treatment of CRC.
    Journal
    |
    TYRO3 (TYRO3 Protein Tyrosine Kinase)
    over1year
    Targeting MERTK on tumour cells and macrophages: a potential intervention for sporadic and NF2-related meningioma and schwannoma tumours. (PubMed, Oncogene)
    UNC2025 was effective in both tumour types with superior efficacy over BGB324. Finally, we found that TAMs are expressed by tumour-associated macrophages in meningioma and schwannoma tumours and that UNC2025 strongly depleted macrophages in both tumour types.
    Journal • Tumor cell
    |
    FLT3 (Fms-related tyrosine kinase 3) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • GAS6 (Growth arrest specific 6) • TYRO3 (TYRO3 Protein Tyrosine Kinase)
    |
    bemcentinib (BGB324) • UNC2025
    2years
    Prognostic DNA mutation and mRNA expression analysis of perineural invasion in oral squamous cell carcinoma. (PubMed, Sci Rep)
    EMT upregulation aligned with the TGFBR1 DNA mutation, supporting its significance in PNI. These findings suggest a potential role of PNI genes in the prognosis of OSCC, providing insights for diagnosis and treatment of OSCC.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • TYRO3 (TYRO3 Protein Tyrosine Kinase) • STAT5A (Signal Transducer And Activator Of Transcription 5A) • TGFBR1 (Transforming Growth Factor Beta Receptor 1)
    2years
    MegaMOST: A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (clinicaltrials.gov)
    P2, N=425, Recruiting, Centre Leon Berard
    Trial completion date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • FLT3 (Fms-related tyrosine kinase 3) • NRAS (Neuroblastoma RAS viral oncogene homolog) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • HRAS (Harvey rat sarcoma viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NF1 (Neurofibromin 1) • AXL (AXL Receptor Tyrosine Kinase) • CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • SMAD4 (SMAD family member 4) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • FLT1 (Fms-related tyrosine kinase 1) • CDK6 (Cyclin-dependent kinase 6) • CCND3 (Cyclin D3) • TYRO3 (TYRO3 Protein Tyrosine Kinase) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)
    over2years
    Tyro3 and CDK9 as biomarkers for drug resistance to breast cancer anti-PD-1 therapies (PubMed, Zhonghua Zhong Liu Za Zhi)
    Tyro3 and CDK9 are associated with the drug resistance to anti-PD-1 therapies for breast cancer. Inhibiting the expression of Tyro3 and CDK9 can reverse the drug resistance to breast cancer treatment.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    AXL (AXL Receptor Tyrosine Kinase) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • TYRO3 (TYRO3 Protein Tyrosine Kinase) • CDK9 (Cyclin Dependent Kinase 9)
    |
    PD-L1 expression • MERTK expression
    almost3years
    Overexpression of TYRO3 indicates poor prognosis and induces gastric cancer progression via AKT-mTOR pathway. (PubMed, Mol Carcinog)
    Moreover, the oncogenic role of TYRO3 was determined through in vitro and in vivo functional assays, and knockdown of the TYRO3 expression level in GC cell lines can effectively suppress the AKT-mTOR pathway and inhibit tumor cell proliferation and migration. In conclusion, this study provides a theoretical basis for establishing the potential association and regulatory mechanism between TYRO3 and AKT-mTOR and offers a new strategy for GC-targeted therapy.
    Journal
    |
    TYRO3 (TYRO3 Protein Tyrosine Kinase)
    almost3years
    TYRO3 promotes tumorigenesis and drug resistance in colorectal cancer by enhancing the epithelial-mesenchymal transition process. (PubMed, Aging (Albany NY))
    Additionally, TYRO3 could inhibit the EMT process by down-regulating ENO1, which may be achieved by interfering with energy metabolism in cancer cells. Therefore, the current study provides a theoretical basis for TYRO3 in drug-resistance of CRC cells and highlights a new strategy for CRC-targeted therapy.
    Journal
    |
    TYRO3 (TYRO3 Protein Tyrosine Kinase) • ENO1 (Enolase 1)